SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026 Responding to patients’

#SCYX SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/SCYX/scynexis-repor...

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 SCYNEXIS (NASDAQ: SCYX) announced dosing of first participants in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of intravenous SCY-247 for invasive candidiasis and prophylaxis against invasive fungal disease. FDA QIDP and Fast Track designations were previously granted. Results from the IV trial are expected in 2026. The company noted positive SAD/MAD oral SCY-247 data in September 2025 showing target exposures at lower doses and is exploring non-dilutive funding to support the program.

#SCYX SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

www.stocktitan.net/news/SCYX/scynexis-annou...

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 SCYNEXIS (NASDAQ: SCYX) announced that the U.S. FDA granted QIDP and Fast Track designations for its second‑generation triterpenoid antifungal, SCY-247. The company noted QIDP will provide at least 10 years of post‑approval market exclusivity and Fast Track may enable more frequent FDA interaction, rolling review, and eligibility for accelerated approval or priority review. SCYNEXIS plans to initiate a Phase 1 IV study and a Phase 2 oral study in invasive candidiasis in 2026, and aims to release oral proof‑of‑concept data the same year. SCY-247 has shown preclinical activity against multi‑drug resistant fungi including Candida auris and azole‑resistant Aspergillus.

#SCYX SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

www.stocktitan.net/news/SCYX/scynexis-recei...

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement SCYNEXIS (NASDAQ: SCYX) received a 180-calendar-day extension from Nasdaq to regain compliance with the minimum bid price rule, extending the cure period to June 15, 2026.Nasdaq confirmed SCYNEXIS meets other continued listing criteria and the company said it may use a reverse stock split if needed. Management also confirmed plans to complete a Phase 1 IV study and seek proof-of-concept Phase 2 oral data for investigational antifungal SCY-247 in invasive candidiasis, while maintaining commitments to regain full Nasdaq compliance.

#SCYX SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

www.stocktitan.net/news/SCYX/scynexis-grant...

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s request to terminate the study. Following the positive SAD/MAD data results

#SCYX SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/SCYX/scynexis-repor...

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis will promptly wind-down and terminate the MARIO study The payment from GSK, combined with cash in hand and removal of future MARIO expenditures,

#SCYX SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

www.stocktitan.net/news/SCYX/scynexis-and-g...

Trade Alerts, Tuesday September 30, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Tue Sept 30th - #ATCH #NBY #YAAS #RAYA #GOVX #FLY #BIAF #ABEB #SCYX #CREG #CLGN #BNRG - More: crystalequityresearch.com/trade-alerts... - #smallcap

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) SCYNEXIS (NASDAQ: SCYX) announced multiple presentations highlighting data for its second-generation fungerp drug candidate SCY-247 at the upcoming TIMM-12 Congress in Bilbao, Spain (September 19-22, 2025). The data demonstrates SCY-247's potent activity against difficult-to-treat fungal infections, particularly Candida auris, including strains resistant to current treatments.The six presentations showcase SCY-247's broad-spectrum antifungal activity against various Candida species and Aspergillus species, including multidrug- and pandrug-resistant strains. Key findings include lower MICs for C. auris compared to echinocandins, effectiveness against 300 C. auris isolates from the New York area, and significant activity in mouse models of invasive candidiasis.The company expects to report Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) trial results for oral SCY-247 in Q3 2025.

#SCYX SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

www.stocktitan.net/news/SCYX/scynexis-annou...

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update SCYNEXIS (NASDAQ: SCYX) reported Q2 2025 financial results and significant corporate developments. The company achieved a major milestone with the first patient dosed in the Phase 3 MARIO study after FDA's clinical hold lift, triggering a disputed $10M milestone payment from GSK, with an additional $20M milestone pending at the six-month mark.Key financial metrics include Q2 2025 revenue of $1.4M, a net loss of $6.9M, and cash reserves of $46.5M providing runway into Q4 2026. R&D expenses increased 5% to $7.1M, while SG&A expenses rose 20% to $3.8M.The company is working to transfer the BREXAFEMME NDA to GSK by end-2025 for potential 2026 relaunch. Additionally, SCYNEXIS expects to report Phase 1 SAD/MAD data for its second-generation fungerp candidate SCY-247 in Q3 2025.

#SCYX SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/SCYX/scynexis-repor...

SCYNEXIS Restarts Critical Phase 3 Trial for Life-Threatening Infection, Faces $30M GSK Payment Battle New patient dosed in antifungal therapy trial following FDA hold resolution. Stakes rise with $30M milestone dispute between SCYNEXIS and GSK. Get trial details.

#SCYX SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

www.stocktitan.net/news/SCYX/scynexis-resum...

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update SCYNEXIS (NASDAQ: SCYX) reported Q1 2025 financial results and key developments. The FDA lifted the clinical hold on ibrexafungerp, but SCYNEXIS faces a disagreement with GSK regarding the restart of the Phase 3 MARIO study for invasive candidiasis treatment. GSK maintains commitment to Brexafemme commercialization. In China, Hansoh received NMPA approval for ibrexafungerp in acute VVC treatment, triggering future milestone payments and ~10% royalties. The company presented positive preclinical data for SCY-247, its second-generation fungerp candidate, with Phase 1 results expected in Q3 2025. Financial highlights include: Q1 net loss of $5.4 million ($0.11 per share), revenue of $0.3 million, and cash position of $53.8 million providing runway into Q3 2026.

#SCYX SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/SCYX/scynexis-repor...

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update SCYNEXIS (NASDAQ: SCYX) reported its full year 2024 financial results, highlighting key developments in its antifungal pipeline. The company's Phase 1 trial of SCY-247, initiated in December 2024, is progressing with results expected in Q3 2025. The company reported a net loss of $21.3 million ($0.44 per basic share) for 2024, compared to a net income of $67.0 million in 2023.Financial highlights include revenue of $3.7 million from the GSK license agreement and a $10 million milestone payment from GSK. R&D expenses decreased by 14.6% to $26.4 million, while SG&A expenses reduced by 30.9% to $14.5 million. The company ended 2024 with cash, cash equivalents and investments of $75.1 million, projecting runway into Q3 2026.SCYNEXIS anticipates restarting its Phase 3 MARIO study in invasive candidiasis in Q2 2025, pending FDA's lifting of the clinical hold.

#SCYX SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/SCYX/scynexis-repor...

SCYNEXIS Launches Pivotal Phase 1 Trial for Novel Antifungal Drug Against Deadly Infections SCYNEXIS advances fight against severe fungal infections with SCY-247 clinical trial launch. New drug shows promise against WHO-listed priority pathogens.

#SCYX SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

www.stocktitan.net/news/SCYX/scynexis-initi...

BREAKING NEWS: ( NASDAQ: #SCYX ) SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

#StockMarket #News